Lixarkitug samrotecan

萨康立沙奇塔单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameLixarkitug samrotecan
Drug Alias NameAZD9829AZD-9829
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload
Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-CD123
TargetsDNA topoisomerase IInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic DiseasesHematologic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanItaly +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesBaxter Oncology GmbhAstrazeneca AbAstraZeneca global R & D (China) Co Ltd
Active IndicationsHematologic Neoplasms
Inactive IndicationsMyelodysplastic SyndromesHematologic DiseasesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A